A Novel Single-Stranded RNA-Based Adjuvant Improves the Immunogenicity of the SARS-CoV-2 Recombinant Protein Vaccine
The research and development (R&D) of novel adjuvants is an effective measure for improving the immunogenicity of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) recombinant protein vaccine. Toward this end, we designed a novel single-stranded RNA-based adjuvant, L2, from the SA...
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-08-01
|
| Series: | Viruses |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1999-4915/14/9/1854 |
| _version_ | 1797481452272615424 |
|---|---|
| author | Dong Liu Chaoqiang An Yu Bai Kelei Li Jianyang Liu Qian Wang Qian He Ziyang Song Jialu Zhang Lifang Song Bopei Cui Qunying Mao Wei Jiang Zhenglun Liang |
| author_facet | Dong Liu Chaoqiang An Yu Bai Kelei Li Jianyang Liu Qian Wang Qian He Ziyang Song Jialu Zhang Lifang Song Bopei Cui Qunying Mao Wei Jiang Zhenglun Liang |
| author_sort | Dong Liu |
| collection | DOAJ |
| description | The research and development (R&D) of novel adjuvants is an effective measure for improving the immunogenicity of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) recombinant protein vaccine. Toward this end, we designed a novel single-stranded RNA-based adjuvant, L2, from the SARS-CoV-2 prototype genome. L2 could initiate retinoic acid-inducible gene-I signaling pathways to effectively activate the innate immunity. ZF2001, an aluminum hydroxide (Al) adjuvanted SARS-CoV-2 recombinant receptor binding domain (RBD) subunit vaccine with emergency use authorization in China, was used for comparison. L2, with adjuvant compatibility with RBD, elevated the antibody response to a level more than that achieved with Al, CpG 7909, or poly(I:C) as adjuvants in mice. L2 plus Al with composite adjuvant compatibility with RBD markedly improved the immunogenicity of ZF2001; in particular, neutralizing antibody titers increased by about 44-fold for Omicron, and the combination also induced higher levels of antibodies than CpG 7909/poly(I:C) plus Al in mice. Moreover, L2 and L2 plus Al effectively improved the Th1 immune response, rather than the Th2 immune response. Taken together, L2, used as an adjuvant, enhanced the immune response of the SARS-CoV-2 recombinant RBD protein vaccine in mice. These findings should provide a basis for the R&D of novel RNA-based adjuvants. |
| first_indexed | 2024-03-09T22:15:47Z |
| format | Article |
| id | doaj.art-f10f605b262b4272a916e1dcd355e572 |
| institution | Directory Open Access Journal |
| issn | 1999-4915 |
| language | English |
| last_indexed | 2024-03-09T22:15:47Z |
| publishDate | 2022-08-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Viruses |
| spelling | doaj.art-f10f605b262b4272a916e1dcd355e5722023-11-23T19:25:09ZengMDPI AGViruses1999-49152022-08-01149185410.3390/v14091854A Novel Single-Stranded RNA-Based Adjuvant Improves the Immunogenicity of the SARS-CoV-2 Recombinant Protein VaccineDong Liu0Chaoqiang An1Yu Bai2Kelei Li3Jianyang Liu4Qian Wang5Qian He6Ziyang Song7Jialu Zhang8Lifang Song9Bopei Cui10Qunying Mao11Wei Jiang12Zhenglun Liang13Division of Hepatitis and Enterovirus Vaccines, NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, Institute of Biological Products, National Institutes for Food and Drug Control, Beijing 102600, ChinaDivision of Hepatitis and Enterovirus Vaccines, NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, Institute of Biological Products, National Institutes for Food and Drug Control, Beijing 102600, ChinaDivision of Hepatitis and Enterovirus Vaccines, NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, Institute of Biological Products, National Institutes for Food and Drug Control, Beijing 102600, ChinaBeijing Minhai Biotechnology Co., Ltd., Beijing 102629, ChinaDivision of Hepatitis and Enterovirus Vaccines, NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, Institute of Biological Products, National Institutes for Food and Drug Control, Beijing 102600, ChinaDivision of Hepatitis and Enterovirus Vaccines, NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, Institute of Biological Products, National Institutes for Food and Drug Control, Beijing 102600, ChinaDivision of Hepatitis and Enterovirus Vaccines, NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, Institute of Biological Products, National Institutes for Food and Drug Control, Beijing 102600, ChinaDivision of Hepatitis and Enterovirus Vaccines, NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, Institute of Biological Products, National Institutes for Food and Drug Control, Beijing 102600, ChinaDivision of Hepatitis and Enterovirus Vaccines, NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, Institute of Biological Products, National Institutes for Food and Drug Control, Beijing 102600, ChinaDivision of Hepatitis and Enterovirus Vaccines, NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, Institute of Biological Products, National Institutes for Food and Drug Control, Beijing 102600, ChinaDivision of Hepatitis and Enterovirus Vaccines, NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, Institute of Biological Products, National Institutes for Food and Drug Control, Beijing 102600, ChinaDivision of Hepatitis and Enterovirus Vaccines, NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, Institute of Biological Products, National Institutes for Food and Drug Control, Beijing 102600, ChinaChangchun Institute of Biological Products Co., Ltd., Changchun 130062, ChinaDivision of Hepatitis and Enterovirus Vaccines, NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, Institute of Biological Products, National Institutes for Food and Drug Control, Beijing 102600, ChinaThe research and development (R&D) of novel adjuvants is an effective measure for improving the immunogenicity of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) recombinant protein vaccine. Toward this end, we designed a novel single-stranded RNA-based adjuvant, L2, from the SARS-CoV-2 prototype genome. L2 could initiate retinoic acid-inducible gene-I signaling pathways to effectively activate the innate immunity. ZF2001, an aluminum hydroxide (Al) adjuvanted SARS-CoV-2 recombinant receptor binding domain (RBD) subunit vaccine with emergency use authorization in China, was used for comparison. L2, with adjuvant compatibility with RBD, elevated the antibody response to a level more than that achieved with Al, CpG 7909, or poly(I:C) as adjuvants in mice. L2 plus Al with composite adjuvant compatibility with RBD markedly improved the immunogenicity of ZF2001; in particular, neutralizing antibody titers increased by about 44-fold for Omicron, and the combination also induced higher levels of antibodies than CpG 7909/poly(I:C) plus Al in mice. Moreover, L2 and L2 plus Al effectively improved the Th1 immune response, rather than the Th2 immune response. Taken together, L2, used as an adjuvant, enhanced the immune response of the SARS-CoV-2 recombinant RBD protein vaccine in mice. These findings should provide a basis for the R&D of novel RNA-based adjuvants.https://www.mdpi.com/1999-4915/14/9/1854single-stranded RNA-based adjuvantimmune responseSARS-CoV-2 recombinant protein vaccine |
| spellingShingle | Dong Liu Chaoqiang An Yu Bai Kelei Li Jianyang Liu Qian Wang Qian He Ziyang Song Jialu Zhang Lifang Song Bopei Cui Qunying Mao Wei Jiang Zhenglun Liang A Novel Single-Stranded RNA-Based Adjuvant Improves the Immunogenicity of the SARS-CoV-2 Recombinant Protein Vaccine Viruses single-stranded RNA-based adjuvant immune response SARS-CoV-2 recombinant protein vaccine |
| title | A Novel Single-Stranded RNA-Based Adjuvant Improves the Immunogenicity of the SARS-CoV-2 Recombinant Protein Vaccine |
| title_full | A Novel Single-Stranded RNA-Based Adjuvant Improves the Immunogenicity of the SARS-CoV-2 Recombinant Protein Vaccine |
| title_fullStr | A Novel Single-Stranded RNA-Based Adjuvant Improves the Immunogenicity of the SARS-CoV-2 Recombinant Protein Vaccine |
| title_full_unstemmed | A Novel Single-Stranded RNA-Based Adjuvant Improves the Immunogenicity of the SARS-CoV-2 Recombinant Protein Vaccine |
| title_short | A Novel Single-Stranded RNA-Based Adjuvant Improves the Immunogenicity of the SARS-CoV-2 Recombinant Protein Vaccine |
| title_sort | novel single stranded rna based adjuvant improves the immunogenicity of the sars cov 2 recombinant protein vaccine |
| topic | single-stranded RNA-based adjuvant immune response SARS-CoV-2 recombinant protein vaccine |
| url | https://www.mdpi.com/1999-4915/14/9/1854 |
| work_keys_str_mv | AT dongliu anovelsinglestrandedrnabasedadjuvantimprovestheimmunogenicityofthesarscov2recombinantproteinvaccine AT chaoqiangan anovelsinglestrandedrnabasedadjuvantimprovestheimmunogenicityofthesarscov2recombinantproteinvaccine AT yubai anovelsinglestrandedrnabasedadjuvantimprovestheimmunogenicityofthesarscov2recombinantproteinvaccine AT keleili anovelsinglestrandedrnabasedadjuvantimprovestheimmunogenicityofthesarscov2recombinantproteinvaccine AT jianyangliu anovelsinglestrandedrnabasedadjuvantimprovestheimmunogenicityofthesarscov2recombinantproteinvaccine AT qianwang anovelsinglestrandedrnabasedadjuvantimprovestheimmunogenicityofthesarscov2recombinantproteinvaccine AT qianhe anovelsinglestrandedrnabasedadjuvantimprovestheimmunogenicityofthesarscov2recombinantproteinvaccine AT ziyangsong anovelsinglestrandedrnabasedadjuvantimprovestheimmunogenicityofthesarscov2recombinantproteinvaccine AT jialuzhang anovelsinglestrandedrnabasedadjuvantimprovestheimmunogenicityofthesarscov2recombinantproteinvaccine AT lifangsong anovelsinglestrandedrnabasedadjuvantimprovestheimmunogenicityofthesarscov2recombinantproteinvaccine AT bopeicui anovelsinglestrandedrnabasedadjuvantimprovestheimmunogenicityofthesarscov2recombinantproteinvaccine AT qunyingmao anovelsinglestrandedrnabasedadjuvantimprovestheimmunogenicityofthesarscov2recombinantproteinvaccine AT weijiang anovelsinglestrandedrnabasedadjuvantimprovestheimmunogenicityofthesarscov2recombinantproteinvaccine AT zhenglunliang anovelsinglestrandedrnabasedadjuvantimprovestheimmunogenicityofthesarscov2recombinantproteinvaccine AT dongliu novelsinglestrandedrnabasedadjuvantimprovestheimmunogenicityofthesarscov2recombinantproteinvaccine AT chaoqiangan novelsinglestrandedrnabasedadjuvantimprovestheimmunogenicityofthesarscov2recombinantproteinvaccine AT yubai novelsinglestrandedrnabasedadjuvantimprovestheimmunogenicityofthesarscov2recombinantproteinvaccine AT keleili novelsinglestrandedrnabasedadjuvantimprovestheimmunogenicityofthesarscov2recombinantproteinvaccine AT jianyangliu novelsinglestrandedrnabasedadjuvantimprovestheimmunogenicityofthesarscov2recombinantproteinvaccine AT qianwang novelsinglestrandedrnabasedadjuvantimprovestheimmunogenicityofthesarscov2recombinantproteinvaccine AT qianhe novelsinglestrandedrnabasedadjuvantimprovestheimmunogenicityofthesarscov2recombinantproteinvaccine AT ziyangsong novelsinglestrandedrnabasedadjuvantimprovestheimmunogenicityofthesarscov2recombinantproteinvaccine AT jialuzhang novelsinglestrandedrnabasedadjuvantimprovestheimmunogenicityofthesarscov2recombinantproteinvaccine AT lifangsong novelsinglestrandedrnabasedadjuvantimprovestheimmunogenicityofthesarscov2recombinantproteinvaccine AT bopeicui novelsinglestrandedrnabasedadjuvantimprovestheimmunogenicityofthesarscov2recombinantproteinvaccine AT qunyingmao novelsinglestrandedrnabasedadjuvantimprovestheimmunogenicityofthesarscov2recombinantproteinvaccine AT weijiang novelsinglestrandedrnabasedadjuvantimprovestheimmunogenicityofthesarscov2recombinantproteinvaccine AT zhenglunliang novelsinglestrandedrnabasedadjuvantimprovestheimmunogenicityofthesarscov2recombinantproteinvaccine |